MwanzoB1NT34 • BVMF
add
BioNTech SE
Bei iliyotangulia
R$ 27.85
Bei za siku
R$ 27.85 - R$ 27.85
Bei za mwaka
R$ 25.78 - R$ 43.61
Thamani ya kampuni katika soko
22.45B USD
Wastani wa hisa zilizouzwa
919.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Habari za soko
Yahoo Finance
saa 1 iliyopita
Starbucks Governance Shifts And Nashville Office Put Turnaround In Focus
0.10%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 907.40M | -23.75% |
Matumizi ya uendeshaji wa biashara | 907.20M | 15.13% |
Mapato halisi | -305.00M | -217.53% |
Kiwango cha faida halisi | -33.61 | -254.10% |
Mapato kwa kila hisa | -0.33 | -130.56% |
EBITDA | -266.95M | -195.92% |
Asilimia ya kodi ya mapato | -34.12% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 13.74B | -13.28% |
Jumla ya mali | 21.99B | -2.40% |
Jumla ya dhima | 2.76B | -11.36% |
Jumla ya hisa | 19.22B | — |
hisa zilizosalia | 239.97M | — |
Uwiano wa bei na thamani | 0.36 | — |
Faida inayotokana na mali | -3.49% | — |
Faida inayotokana mtaji | -3.96% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -305.00M | -217.53% |
Pesa kutokana na shughuli | 309.50M | 166.80% |
Pesa kutokana na uwekezaji | -2.73B | -549.25% |
Pesa kutokana na ufadhili | -14.30M | -95.89% |
Mabadiliko halisi ya pesa taslimu | -2.42B | -1,860.74% |
Mtiririko huru wa pesa | -1.44B | -27.63% |
Kuhusu
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2008
Tovuti
Wafanyakazi
7,807
